Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PREVAIL 1: A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

Next Previous
Trial Profile

PREVAIL 1: A Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRV 3279 (Primary)
  • Indications Autoimmune disorders; Systemic lupus erythematosus
  • Focus Adverse reactions; Proof of concept
  • Acronyms PREVAIL; PREVAIL 1
  • Sponsors Provention Bio

Most Recent Events

  • 06 May 2021 According to a Provention Bio media release, data from this study is planned to be submitted for presentation at an upcoming medical conference later in 2021.
  • 12 Mar 2020 According to an Provention Bio media release, based on the results from the Phase 1b portion, the company plans to commence the Phase 2a portion in lupus patients in the first half of 2021.
  • 12 Mar 2020 Results from Phase 1b portion published in the Provention Bio Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top